Preferred Label : multi-centric castleman's disease;

CISMeF synonym : HHV-8-Associated multicentric castleman disease;

MeSH synonym : plasmablastic multicentric castleman disease; multicentric plasma cell variant of castleman's disease; multicentric castleman's disease;

MeSH hyponym : thrombocytopenia anasarca fever renal dysfunction and organomegaly syndrome; TAFRO HHV-8-negative multicentric Castleman disease.; KSHV Muticentric Castleman Disease; KSHV-Associated Multicentric Castleman Disease; HHV8 Multicentric Castleman Disease; Idiopathic multicentric Castleman's disease; HHV-8-negative MCD;

Is substance : O;

Details


Main resources

You can consult :


Summary Basis of Decision (SBD) for Sylvant
Siltuximab, 100 mg/vial and 400 mg/vial, Lyophilized powder for solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?linkID=SBD00193
2015
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
siltuximab
siltuximab
siltuximab
drug evaluation
risk assessment
treatment outcome
Interleukin-6
multi-centric castleman's disease
adult
rare diseases
infusions, intravenous
Castleman Disease
antibodies, monoclonal
antibodies, monoclonal

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=93686
2011
France
scientific and technical information
Castleman Disease
multi-centric castleman's disease
Multi-centric Castleman's Disease

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.